Navigation Links
Studies look at how genes affect antipsychotic drug response

Researchers at the University of Illinois at Chicago College of Pharmacy are attempting to discover how genes determine how well an antipsychotic medication works in adults and children and the side effects it will cause.

Risperidone, a popular "atypical" antipsychotic medication, is used to treat mental illnesses such as schizophrenia and bipolar disorder.

Jeffrey Bishop, assistant professor of pharmacy practice, is examining the effects of one gene, catechol-o-methyltransferase, on brain activity, cognition and symptom response to the drug.

The study is being done in adults who are experiencing their first episode of schizophrenia who are treated with risperidone for six weeks as part of UIC's First Episode Program.

"Allowing patients with schizophrenia an increased chance at medication response literally could change their lives," Bishop said.

"While we know a great deal about the pharmacology of antipsychotics like risperidone, there is still much to learn about their influence on cognition and brain function, as well as how genetics affect overall medication response," he said.

Bishop says the project will serve as a first step toward a comprehensive pharmacogenetic analysis of metabolic pathways affecting response to the drug. He was presented with an award for new investigators from the American College of Clinical Pharmacy for the project.

The UIC Center for Cognitive Medicine's First Episode Program, directed by Dr. John Sweeney, has been studying patients with first-episode schizophrenia for the past five years.

Bishop is also beginning a second project to study how risperidone may elevate prolactin levels and cause weight gain in children ages 8-18 who suffer from pediatric bipolar disorder. An increase in prolactin (a pituitary hormone that may affect bone development) or weight gain occurs in some but not all of these young patients.

"We are trying to determine if some kids are at a greater risk than others for these problems by analyzing genetic markers," Bishop said.

Bishop said if children are to receive long-term drug therapy, clinicians need to make sure they are appropriately monitored and treated as safely as possible.

"Understanding risperidone pharmacogenetics and whether some individuals are at a higher risk for side effects is an important step in this process," he said.

Risperidone is widely prescribed to treat bipolar disorder in children, accounting for half of all atypical antipsychotic prescriptions in pediatric psychiatry. Adverse drug effects, such as weight gain and the possibility of prolactin elevation, are often dose-limiting and affect medication compliance.


'"/>

Source:University of Illinois at Chicago


Related biology news :

1. Studies reveal methods viruses use to sidestep immune system
2. Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine
3. Studies clarify risk factors for mother-to-child transmission of hepatitis C virus
4. Studies on human genome variation provide insight into disease
5. Studies suggest new brain protein may help in treating schizophrenia, insomnia and anxiety
6. Studies find general mechanism of cellular aging
7. Studies yield insight into the numerical brain
8. Studies force new view on biology of flavonoids
9. Newly-discovered class of genes determines ?and restricts ?stem cell fate
10. Inexpensive, mass-produced genes core of synthetic biology advances at UH
11. First atlas of key brain genes could speed research on cancer, neurological diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... 22, 2017 , ... AESKU.GROUP, an innovation leader in ... Technologien GmbH, thereby expanding its product portfolio to include allergy and food intolerance ... atopic eczema or a food allergy. Allergies are escalating to epidemic proportions and ...
(Date:6/22/2017)... ... 2017 , ... RURO, Inc., a leading LIMS, RFID, and ... update to the Limfinity® framework. , LimitLIS® and other RURO solutions based on ... customers among labs and other businesses. Limfinity® 6.5 adds new features and improvements ...
(Date:6/20/2017)... Pa. , June 20, 2017  Kibow Biotech ... pleased to announce the issuance of a new patent ... or hyperuricemia by the U.S. Patent and Trademark Office ... a winner of the Buzz of Bio award in ... is akin to developing non-drug approaches to chronic disease. ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... solutions for clinical development reported today that it is launching two new additions ... company will be demonstrating new capabilities at the DIA 2017 Annual Meeting in ...
Breaking Biology Technology: